The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Epidermal Growth Factor Receptor Mutations in Non–Small-Cell Lung Cancer: Implications for Treatment and Tumor Biology
Abstract
The epidermal growth factor receptor (EGFR) has emerged as an attractive therapeutic target for patients with non–small-cell lung cancer (NSCLC). However, despite its almost universal presence in NSCLC tumors, therapeutic inhibition of EGFR has resulted in significant tumor regressions in only 10% to 20% of patients. Several investigations over the last 12 months have uncovered somatic mutations in EGFR that underlie the sensitivity to EGFR inhibitors. NSCLC tumors and cell lines with EGFR mutations are exquisitely sensitive to the EGFR tyrosine kinase inhibitors (TKIs), erlotinib and gefitinib, and are biologically distinct from other forms of NSCLC. Somatic mutations in EGFR are found more frequently in patients with adenocarcinomas, nonsmokers, patients of Asian ethnicity, and in females. EGFR mutation detection is now becoming clinically available and is being incorporated into clinical treatment decisions and into the design of future clinical trials. Mutations in K-ras, a mediator of EGFR signaling, are mutually exclusive with EGFR mutations, and are associated with resistance to EGFR TKIs. In addition, secondary mutations, conferring resistance to EGFR TKIs, in patients with primary EGFR mutations once sensitive to EGFR TKIs, are beginning to be identified. The frequency of EGFR mutations, their impact on NSCLC biology, clinical treatment, and clinical trial design, as well as methods and limitations for mutation detection, will be reviewed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citationComparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., & Johnson, D. H. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011954 · Cited by 4,955
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Jemal, A., Murray, T., Ward, E., Samuels, A., Tiwari, R. C., Ghafoor, A., Feuer, E. J., & Thun, M. J. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.1.10 · Cited by 4,186
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Self-citationCOMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
Fukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J.-Y., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.038 · Cited by 2,874
Cited by
Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship
Molina, J. R., Yang, P., Cassivi, S. D., Schild, S. E., & Adjei, A. A. (2008) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(11)60735-0 · Cited by 3,908
Epidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
Li, D., Ambrogio, L., Shimamura, T., Kubo, S., Takahashi, M., Chirieac, L. R., Padera, R. F., Shapiro, G. I., Baum, A., Himmelsbach, F., et al. (2008) · Oncogene · doi:10.1038/onc.2008.109 · Cited by 1,447
Khambata-Ford, S., Garrett, C. R., Meropol, N. J., Basik, M., Harbison, C. T., Wu, S., Wong, T. W., Huang, X., Takimoto, C. H., Godwin, A. K., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.5437 · Cited by 1,125
Mechanisms of receptor tyrosine kinase activation in cancer
Du, Z., & Lovly, C. M. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0782-4 · Cited by 1,066
Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449
Rudin, C. M., Hann, C. L., Laterra, J., Yauch, R. L., Callahan, C. A., Fu, L., Holcomb, T., Stinson, J., Gould, S. E., Coleman, B., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902903 · Cited by 1,019
Zhang, Y.-L., Yuan, J.-Q., Wang, K.-F., Fu, X.-H., Han, X.-R., Threapleton, D., Yang, Z.-Y., Mao, C., & Tang, J.-L. (2016) · Oncotarget · doi:10.18632/oncotarget.12587 · Cited by 799
Glioblastoma: pathology, molecular mechanisms and markers
Aldape, K., Zadeh, G., Mansouri, S., Reifenberger, G., & von Deimling, A. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1432-1 · Cited by 735
Engelman, J. A., Zejnullahu, K., Gale, C.-M., Lifshits, E., Gonzales, A. J., Shimamura, T., Zhao, F., Vincent, P. W., Naumov, G. N., Bradner, J. E., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1885 · Cited by 730
Self-citationEngelman, J. A., & Jänne, P. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2248 · Cited by 703
Self-citationMassarelli, E., Varella-Garcia, M., Tang, X., Xavier, A. C., Ozburn, N. C., Liu, D. D., Bekele, B. N., Herbst, R. S., & Wistuba, I. I. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3043 · Cited by 597
Emerging insights into the molecular and cellular basis of glioblastoma
Dunn, G. P., Rinne, M. L., Wykosky, J., Genovese, G., Quayle, S. N., Dunn, I. F., Agarwalla, P. K., Chheda, M. G., Campos, B., Wang, A., et al. (2012) · Genes & Development · doi:10.1101/gad.187922.112 · Cited by 565
KRAS Mutations in Non-Small Cell Lung Cancer
Riely, G. J., Marks, J., & Pao, W. (2009) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200809-107lc · Cited by 550
Inoue, A., Suzuki, T., Fukuhara, T., Maemondo, M., Kimura, Y., Morikawa, N., Watanabe, H., Saijo, Y., & Nukiwa, T. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.4692 · Cited by 509
Yauch, R. L., Januario, T., Eberhard, D. A., Cavet, G., Zhu, W., Fu, L., Pham, T. Q., Soriano, R., Stinson, J., Seshagiri, S., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1492 · Cited by 495
Jinushi, M., Chiba, S., Yoshiyama, H., Masutomi, K., Kinoshita, I., Dosaka-Akita, H., Yagita, H., Takaoka, A., & Tahara, H. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1106645108 · Cited by 479
Ji, H., Li, D., Chen, L., Shimamura, T., Kobayashi, S., McNamara, K., Mahmood, U., Mitchell, A., Sun, Y., Al-Hashem, R., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.04.022 · Cited by 462
Self-citationMutation analysis of 24 known cancer genes in the NCI-60 cell line set
Ikediobi, O. N., Davies, H., Bignell, G., Edkins, S., Stevens, C., O'Meara, S., Santarius, T., Avis, T., Barthorpe, S., Brackenbury, L., et al. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0433 · Cited by 440
Somatic Mutations Drive Distinct Imaging Phenotypes in Lung Cancer
Rios Velazquez, E., Parmar, C., Liu, Y., Coroller, T. P., Cruz, G., Stringfield, O., Ye, Z., Makrigiorgos, M., Fennessy, F., Mak, R. H., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0122 · Cited by 391
Never-Smokers With Lung Cancer: Epidemiologic Evidence of a Distinct Disease Entity
Toh, C.-K., Gao, F., Lim, W.-T., Leong, S.-S., Fong, K.-W., Yap, S.-P., Hsu, A. A. L., Eng, P., Koong, H.-N., Thirugnanam, A., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.8033 · Cited by 379
McConkey, D. J., Choi, W., Marquis, L., Martin, F., Williams, M. B., Shah, J., Svatek, R., Das, A., Adam, L., Kamat, A., et al. (2009) · Cancer and Metastasis Reviews · doi:10.1007/s10555-009-9194-7 · Cited by 368
Ruggeri, B. A., Camp, F., & Miknyoczki, S. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.06.020 · Cited by 365
Structure and Clinical Relevance of the Epidermal Growth Factor Receptor in Human Cancer
Kumar, A., Petri, E. T., Halmos, B., & Boggon, T. J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.1178 · Cited by 308
Integration of EGFR inhibitors with radiochemotherapy
Nyati, M. K., Morgan, M. A., Feng, F. Y., & Lawrence, T. S. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1953 · Cited by 304
Eberhard, D. A., Giaccone, G., & Johnson, B. E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.9858 · Cited by 300
Self-citationExpression and mutational analysis of MET in human solid cancers
Ma, P. C., Tretiakova, M. S., MacKinnon, A. C., Ramnath, N., Johnson, C., Dietrich, S., Seiwert, T., Christensen, J. G., Jagadeeswaran, R., Krausz, T., et al. (2008) · Genes, Chromosomes and Cancer · doi:10.1002/gcc.20604 · Cited by 300
Molecularly targeted cancer therapy: some lessons from the past decade
Huang, M., Shen, A., Ding, J., & Geng, M. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.11.004 · Cited by 291
The nuclear export protein XPO1 — from biology to targeted therapy
Azmi, A. S., Uddin, M. H., & Mohammad, R. M. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00442-4 · Cited by 279
EGFR amplification and lack of activating mutations in metaplastic breast carcinomas
Reis‐Filho, J., Pinheiro, C., Lambros, M., Milanezi, F., Carvalho, S., Savage, K., Simpson, P., Jones, C., Swift, S., Mackay, A., et al. (2006) · The Journal of Pathology · doi:10.1002/path.2004 · Cited by 266
EGFR-mutated lung cancer: a paradigm of molecular oncology
Zhang, Z., Stiegler, A. L., Boggon, T. J., Kobayashi, S., & Halmos, B. (2010) · Oncotarget · doi:10.18632/oncotarget.186 · Cited by 197
Jänne, P. A., & Johnson, B. E. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0555 · Cited by 147
Self-citation
Metadata
- Authors
- Jänne, P. A., Engelman, J. A., & Johnson, B. E.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-05-10
- Volume
- 23
- Issue
- 14
- Pages
- 3227-3234
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2059780149
- Cited by
- 405
- References
- 56
- FWCI
- 33.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.